Progress In Transcatheter Aortic Valve Implantation

Similar documents
Emergency TAVI: Does It Exist? Is the Risk Higher?

CoreValve Evolut R Technology review and Clinical Results. Paul TL Chiam

Echo Assessment Pre-TAVI

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

Affiliation/Financial Relationship Grant/ Research Support: Major Stock Shareholder/Equity Interest: Royalty Income: Ownership/Founder: Salary:

transcatheter heart valve: THV TAVI transcatheter aortic valve implantation

Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD

Optimal Techniques for Obtaining Large Caliber Arterial Access

Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD

A Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class?

Portico (St. Jude Medical Inc, St.

Transcatheter Aortic Valve Replacement with Evolut-R

TAVI Technology and Procedural Changes

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Eberhard Grube MD, FACC, FSCAI

Emerging Transcatheter Aortic Valve Technologies

TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES

1-YEAR OUTCOMES FROM JOHN WEBB, MD

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

Vascular complications of embolized core valve

TAVR: Current Valve Types. Patient Selection

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

What will be the TAVI's future? Which developments can we still expect in the forthcoming years?

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

Aortic stenosis (AS) remains the most common

My Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.

3 rd TAVI Summit Seoul, August 9/10, 2013

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

TAVR for low-risk patients in 2017: not so fast.

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

Transcatheter Aortic Valve Implantation Present Status and Perspectives

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

SAPIEN 3 Sizing Considerations:

Update on Transcatheter Mitral Valve Repair and Replacment

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

Lotus Valve System for Transcatheter Aortic Valve Implantation/Replacement (TAVI/R) Evidence

TAVI: FUTURE DEVELOPMENTS

TAVI: Present and Future Perspective

Over the past 10 years, transcatheter aortic valve

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

TAVI limitations for low risk patients

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

TAVR for Complex Aortic Valvular Conditions

Pacemaker rates Second generation TAVI Devices

TAVR SPRING 2017 The evolution of TAVR

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Eduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine University of

Current Evidence in TAVI patients using ACURATE and LOTUS valves

Transcatheter Aortic Valve Replacement

Interventional Cardiology

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Transcatheter aortic valve implantation: a revolution in the therapy of elderly and high-risk patients with severe aortic stenosis

Chapter 39 Transcatheter Aortic Valves: Types of Available Valves

The Lotus Valve, The Latest Developments and Future Aspects. Professor Jan Harnek MD PhD FESC Lund University Sweden

TAVI: Transapical Procedures

One-year outcomes with the transcatheter LOTUS Edge Aortic Valve System

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

Nouvelles indications/ Nouvelles valves

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Trans Catheter Aortic Valve Replacement

TAVI EN INSUFICIENCIA AORTICA

Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011

Since the first-in-human transcatheter aortic valve

Transcatheter Aortic Valve Replacement With a New Self-Expanding Transcatheter Heart Valve and Motorized Delivery System

Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD

I will not discuss off label use or investigational use in my presentation.

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

Conflicts of interests

The Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

From Dream to Reality. The PVT Story

Conflicts of interests

TAVI: Nouveaux Horizons

PORTICO CE TRIAL ASSESSMENT OF THE ST. JUDE MEDICAL PORTICO TRANSCATHETER AORTIC VALVE IMPLANT AND THE TRANSFEMORAL DELIVERY SYSTEM

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

Transcatheter Mitral Valve Replacement How Close Are We?

Transcatheter Valve Replacement: Current State in 2017

CoreValve in a Degenerative Surgical Valve

Alternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy

Current Controversies. Subclinical and clinical valve thrombosis

Evolut R in bicuspid valve anatomies

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

Transcatheter Pulmonary Valve Replacement Update on progress and outcomes

Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and

Portico Transcatheter Aortic Valve Implantation System. portico PRECISION

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland

MITRAL (Mitral Implantation of TRAnscatheter valves)

Early Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

Transcription:

Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below Affiliation/Financial Relationship Grant/ Research Support: Consulting Fees/Honoraria: Company Edwards Lifesciences (consultant & proctor) Major Stock Shareholder/Equity Interest: Royalty Income: Ownership/Founder: Salary: Intellectual Property Rights: Other Financial Benefit:

Lots of progress TAVR Manuscriptes in Pub Med 2012 and 20132 (thusfar) 900 800 700 600 500 400 300 200 100 0 Pub Med reviewed 835 532 303 (5 months) 2012 2013 Total

New Devices in TAVR Embolic protection devices New transcatheter valves

NEW TRANSCATHETER VALVES

Edwards SAPIEN 3 Edwards Centera Medtronic CoreValve Evolut Boston Scientific Lotus Direct Flow Medical St Jude Portico

Edwards SAPIEN 3 Balloon expandable system Cobalt chromium frame Bovine pericardiac tissue Longer 20mm Outer sealing skirt to reduced paravalvular regurg. Size: 23mm, 26mm, 29mm 14Fr e-sheath for 23 & 26mm valve; 16Fr e-sheath for 29mm valve Commander delivery system for TF Increased flexion incl distal flexion Fine Up and Down control for fine THV positioning Proximal Flex Distal Flex

Edwards Centera Self-expanding Nitinol frame Treated bovine pericardium Contoured frame designed for optimal seating and sealing in the annulus 23 mm, 26 mm, 29 mm sizes 14F esheath Pre-packaged (no loading needed) Motorized handle with touch deployment allows precise THV placement Repositionable Flex mechanism for enhanced trackability and optimal coaxial alignment Distal flex Touch deployment

Medtronic CoreValve Evolut Redesigned release mechanism for ease of separation from delivery catheter Shorted outflow More consistent inflow radial force to reduce paravalvular regurgitation Longer and extended skirt Enveo delivery system Nitinol reinformed capsule for recapturability and repositionability Flexible shaft for nagivation through tortuous anatomy Redesigned handle allowing 1-1 deployment control 14Fr equivalent with In-line Sheath TM

Boston Scientific Lotus Valve Bovine pericardium Nitinol frame Adaptive seal to reduce paravalvular regurgitation 18Fr access Pre-packaged Deployed via mechanical expansion Shortens as it expands Fully recapturable and repositionable even after full deployment 1. Elongated Configuration (for Delivery) ~70 mm 2. Intermediate Configuration 3. Final Locked Configuration 19 mm

Direct Flow Medical Expandable dacron polyester double ring design ie. Metal free! Bovine pericardial leaflets Sealing ring to reduce paravalvular regurgitation 18Fr access 3 positioning lines to adjust position Fully retrievable and repositionable

St Jude Portico Self-expanding Bovine pericardial leaflets Porcine pericardial sealing cuff Large cells to reduce paravalvular regurgication and improve coronary access 18Fr delivery system Fully recapturable and repositionable

Summary SAPIEN 3 Centera CoreValve Evolute Lotus Direct Flow Portico Access TF / TA TF TF TF TF TF /?TA Access size (Fr) 14/16 14 14 18 18 18 Procedural Success 100% 100% 100% 99% 100% Post-TAVR mean gradient / EOA PVL Mild >Mild 30-day Outcomes 13.0mmHg / 1.5cm 2 27% 0 10.6mmHg / 1.6cm 2 69% 8% 13.7mmHg / 1.5cm 2 18% 0 14.1mmHg / 1.43cm 2 26% 1% 13.3mmHg / 1.2cm 2 Death 0 13.3% 0 1.3% 0 Stroke 0 0 9.1% 2.7% 0 Major Vascular 0 0 0 2.7% 0 Life-threatening bleeding 0 6.7% 18.2% 4% 0 PPM 6.7% 27.7% 16% 0 45% 0